The value of FDG combined with PiB PET in the diagnosis of patients with cognitive impairment in a memory clinic

The value of FDG combined with PiB PET in the diagnosis of patients with cognitive impairment in a memory clinic

Aims To analyze the value of 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with amyloid PET in cognitive impairment diagnosis. Methods A total of 187 patients with dementia or mild cognitive impairment (MCI) who underwent 11C‐Pittsburgh compound B (PiB) and FDG PET scans i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CNS neuroscience & therapeutics 2024-02, Vol.30 (2), p.e14418-n/a
Hauptverfasser: Liu, Fang, Shi, Yudi, Wu, Qiuyan, Chen, Huifeng, Wang, Ying, Cai, Li, Zhang, Nan
Format: Artikel
Sprache:eng
Schlagworte:
Advertising executives
Alzheimer's disease
Amyloid
Cognitive ability
cognitive impairment
Cortex (parietal)
Decision making
Dementia
Dementia disorders
Diagnosis
Disease
fluorodeoxyglucose
Health aspects
Memory
memory clinic
Neuropsychology
Original
Pathology
Pathophysiology
PET imaging
Pittsburgh compound B
Positron emission tomography
Tomography
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims To analyze the value of 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with amyloid PET in cognitive impairment diagnosis. Methods A total of 187 patients with dementia or mild cognitive impairment (MCI) who underwent 11C‐Pittsburgh compound B (PiB) and FDG PET scans in a memory clinic were included in the final analysis. Results Amyloid‐positive and amyloid‐negative dementia patient groups showed a significant difference in the proportion of individuals presenting temporoparietal cortex (p 
ISSN:1755-5930
1755-5949
DOI:10.1111/cns.14418